Tofacitinib boxed warning revised effective September 1, 2026

The FDA revised the boxed warning on the tofacitinib label, with the change effective September 1, 2026. The warning identifies serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis as risks associated with treatment with tofacitinib tablets.

The supplied FDA label summary begins with a warning that patients treated with tofacitinib tablets are at increased risk for developing serious bacterial, fungal, viral, and other serious infections.

Background

Tofacitinib is also identified in the supplied record by the names Xeljanz, Xeljanz XR, and tofacitinib citrate. The event concerns a revision to the drug’s boxed warning, the label section used to communicate serious or potentially life-threatening risks. The supplied data do not provide an indication, dosing information, mechanism of action, patient population, or details about prior labeling.

What changed

The revised warning names five risk categories: serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. The available summary specifically states that patients receiving tofacitinib tablets are at increased risk of serious bacterial, fungal, viral, and other serious infections.

The event record does not provide the full revised warning text, supporting study results, risk estimates, affected subgroups, treatment recommendations, or a comparison with another therapy. It therefore documents the label action and the risk categories named in the supplied FDA summary, but not the size of any associated risk or the clinical circumstances in which each risk applies.

What this means

Clinicians and other readers reviewing tofacitinib labeling should consult the revised FDA document before interpreting the warning or applying it to treatment decisions. The effective date is September 1, 2026, and the supplied record identifies the change as a boxed-warning revision rather than a new indication or a dosing update.

Patients and advocates should not infer an individual risk estimate from this event record. The supplied information does not include incidence figures, study names, p-values, confidence intervals, or details about how the revised warning changes prescribing or monitoring.

Source

Source: FDA, revised tofacitinib label document, effective September 1, 2026. The source is available through DailyMed at dailymed.nlm.nih.gov, using set ID 253635c8-1ea7-41ba-b216-dea5e3305c47.